FindTrial
Sign In

Evaluation Of The Efficacy And Safety Of Intrapleural Injection Of Bevacizumab Treatment Of Malignant Pleural Effusion Caused By Lung Adenocarcinoma

Evaluation Of The Efficacy And Safety Of Intrapleural Injection Of Bevacizumab Treatment Of Malignant Pleural Effusion Caused By Lung Adenocarcinoma

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800018768
Enrollment
Unknown
Registered
2018-10-09
Start date
2014-12-01
Completion date
Unknown
Last updated
2018-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Pleural Effusion Caused By Lung Adenocarcinoma

Interventions

bevacizumab group :thoracic perfusion therapy
OK432 group:thoracic perfusion therapy

Sponsors

The Affiliated Hospital of Inner Mongolia Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: patients with lung adenocarcinoma with malignant pleural effusion, confirmed by ultrasonography,

Exclusion criteria

Exclusion criteria: Gastrointestinal perforation and tracheoesophageal fistula in recent 2 months; hemorrhage in recent 2 months: cerebral hemorrhage, hemoptysis, hematuria, hematuria; reversible posterior leukoencephalopathy syndrome; confirmed venous or arterial thromboembolism; severe congestive heart failure; uncontrolled hypertension after adequate antihypertensive treatment; at least 28 days after major surgery The wound was not healed; grade 4 albuminuria; penicillin allergy.

Design outcomes

Primary

MeasureTime frame
volume of pleural effusion;Adverse reaction;serum VEGF;—

Countries

China

Contacts

Public ContactFu xiuhua

The Affiliated Hospital of Inner Mongolia Medical University,

fuxiuhua555@sohu.com+86 13947142625

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026